State Street Corp Increases Stock Holdings in Harrow, Inc. (NASDAQ:HROW)

State Street Corp raised its stake in Harrow, Inc. (NASDAQ:HROW) by 2.2% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 730,973 shares of the company’s stock after purchasing an additional 15,554 shares during the period. State Street Corp’s holdings in Harrow were worth $32,865,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its holdings in Harrow by 16.6% in the second quarter. Bank of New York Mellon Corp now owns 88,210 shares of the company’s stock valued at $1,843,000 after buying an additional 12,580 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Harrow by 2,730.7% during the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock worth $44,000 after purchasing an additional 2,048 shares during the last quarter. nVerses Capital LLC purchased a new position in Harrow in the second quarter valued at approximately $33,000. Drive Wealth Management LLC raised its holdings in Harrow by 63.1% during the second quarter. Drive Wealth Management LLC now owns 29,551 shares of the company’s stock worth $617,000 after purchasing an additional 11,434 shares in the last quarter. Finally, Rhumbline Advisers lifted its position in shares of Harrow by 8.2% during the 2nd quarter. Rhumbline Advisers now owns 43,021 shares of the company’s stock worth $899,000 after buying an additional 3,253 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Wall Street Analysts Forecast Growth

HROW has been the topic of several research reports. Craig Hallum raised their price objective on Harrow from $45.00 to $65.00 and gave the stock a “buy” rating in a report on Friday, October 4th. B. Riley decreased their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating for the company in a report on Wednesday, December 4th. Finally, Lake Street Capital upped their price target on shares of Harrow from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Friday, October 4th.

Harrow Stock Down 0.6 %

HROW opened at $34.22 on Friday. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The business has a 50 day moving average price of $44.55 and a two-hundred day moving average price of $36.65. Harrow, Inc. has a 52 week low of $9.13 and a 52 week high of $59.23. The company has a market cap of $1.22 billion, a PE ratio of -36.40 and a beta of 0.69.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.